From Wikipedia, the free encyclopedia
Jump to: navigation, search
Traded as ABLX[1]
Industry Biotechnology
Key people

Edwin Moses (CEO)

Wim Ottevaere (CFO)
Website www.ablynx.com

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies.


In November 2001, Ablynx was established as a spin-off of the Vlaams Instituut voor Biotechnologie (VIB) and the Free University of Brussels (VUB). Seed financing of €2M was provided by Gimv.[2]

In July 2015 Merck & Co. and Ablynx expanded their 18 month old immuno-oncology collaboration by four years, generating a potential $4.4 billion in milestone payments for Ablynx.[3] In 2015, the Novo Nordisk announced it would collaborate with Ablynx, using its nanobody technology to develop at least one new drug candidate, generating a potential $400 million for the company.[4]


Further reading[edit]

  • Wolfson W., Ablynx makes nanobodies from llama bodies, Chem Biol. 2006 Dec;13(12):1243-4.
  • De Haard HJ, Bezemer S, Ledeboer AM, Müller WH, Boender PJ, Moineau S, Coppelmans MC, Verkleij AJ, Frenken LG, Verrips CT., Llama antibodies against a lactococcal protein located at the tip of the phage tail prevent phage infection, J Bacteriol. 2005 Jul;187(13):4531-41.

External links[edit]